Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 0.8% in the 4th quarter, Holdings Channel reports. The firm owned 797,299 shares of the biopharmaceutical company’s stock after purchasing an additional 6,462 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Revance Therapeutics were worth $2,424,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the business. FORA Capital LLC bought a new stake in shares of Revance Therapeutics in the 3rd quarter worth approximately $54,000. Dynamic Technology Lab Private Ltd acquired a new stake in Revance Therapeutics in the third quarter worth $88,000. Virtu Financial LLC bought a new stake in Revance Therapeutics in the third quarter valued at $120,000. Intech Investment Management LLC acquired a new position in shares of Revance Therapeutics during the third quarter valued at $231,000. Finally, Deltec Asset Management LLC bought a new position in shares of Revance Therapeutics during the fourth quarter worth about $304,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. StockNews.com started coverage on shares of Revance Therapeutics in a research report on Wednesday. They issued a “hold” rating on the stock. Mizuho cut their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. Barclays reduced their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday, December 23rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Price Performance

NASDAQ RVNC opened at $3.65 on Friday. Revance Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $6.65. The firm has a market capitalization of $381.02 million, a PE ratio of -1.89 and a beta of 0.90. The company’s 50 day simple moving average is $3.65 and its 200 day simple moving average is $4.16.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.